Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

Scientists identify new biomarkers that could guide bowel cancer treatment

Scientists identify new biomarkers that could guide bowel cancer treatment

Reduced radiation can maintain high cure rates in patients with HPV-related oropharyngeal cancers

Reduced radiation can maintain high cure rates in patients with HPV-related oropharyngeal cancers

UCLA-led research finds promising results for more personalized head and neck cancer treatment

UCLA-led research finds promising results for more personalized head and neck cancer treatment

Scientists find new way to bypass bowel cancer's defence against treatment

Scientists find new way to bypass bowel cancer's defence against treatment

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Study reveals why colorectal cancer still returns in some patients after treatment

Study reveals why colorectal cancer still returns in some patients after treatment

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Scientists successfully test new tumor diagnosis method

Scientists successfully test new tumor diagnosis method

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients